Prolific Expansion Opportunities Underway for Gemcitabine HCL across Lung Cancer Treatment: Fact.MR

2021-03-15

仿制药

Dearth of highly effective treatment approaches combined with the emergence of more intricate forms of lung cancers is prompting companies to initiate research projects and trials to test the efficacy of gemcitabine HCL in this domain Fact.MR, Rockville MD: Fact.MR has published an extensive report on the global gemcitabine HCL market. According to the study, the market is poised to yield significant gains in 2021, owing to a rejuvenated emphasis to further advanced oncology research. A moderate deceleration was experienced in 2020 as the COVID-19 pandemic reoriented healthcare priorities. In the long-run, growth prospects are likely to reach higher echelons. Gemcitabine HCL has been finding heightened applications to address ovarian, pancreatic, breast and prostate cancers respectively. Presently, while research and development across the aforementioned domains has remained sustained, practitioners are expected to allocate a significant chunk of their resources in developing breakthroughs across non-small cell lung cancer. Studies suggest that lung cancer often has poor prognosis, with over 50% of those diagnosed succumbing within a year of its contraction. While numerous surgical oncologists relied on video-assisted thoracic surgery (VATS), demand for more minimally invasive approaches have paved way for various advancements to ensure fewer post-operative patient complications. This is expected to raise the popularity of gemcitabine HCL usage to manage this condition in forthcoming years. Manufacturers, therefore, are in the process of initiating clinical trials to test the efficacy of this approach. “Prominent manufacturers are increasingly transitioning towards generically manufactured gemcitabine HCL offerings, attributed to their relative ease of production and reduced costs, prompting numerous pharmaceutical companies to increase their foray into India and China, the world’s leading generic drug producers,” remarks the Fact.MR analyst. For More Valuable Information on Regional Market Dynamics, Request a Report Sample Key Takeaways from Fact.MR’s Gemcitabine HCL Market Study Preference for generic gemcitabine HCL formulations to remain intact through 2021 Increasing burden of pancreatic cancer to bolster growth prospects in the long-run Hospitals to remain primary gemcitabine HCL consumers, demand across cancer centers likely to proliferate US to experience high growth amid rising breast cancer diagnosis and treatment procedures Growing prevalence of prostate and bladder cancer to pivot UK market growth Germany & France likely to fund more institutional and clinical level cancer research programs, thus stimulating growth High generic drugs production capability to heighten gemcitabine HCL production across India Gemcitabine HCL Market- Prominent Drivers Increasing burden of numerous cancers is prompting oncologists to incorporate gemcitabine HCL formulations for treatment Healthcare providers are deepening their foray to discover potential therapeutics for treating advanced lung cancers, thus widening growth prospects Key manufacturers are effectively leveraging online sales and connectivity platforms to extend gemcitabine HCL outreach Gemcitabine HCL Market- Key Restraints Documented side effects of products like Gemzar such as nausea and vomiting to restrict uptake of gemcitabine HCL infused products Prolonged waiting lists with respect to new drug formulation approvals by regulatory authorities may lead to delayed product launches Discover more about the gemcitabine HCL market with 91 figures and 92 data tables, along with the table of contents. You will also find detailed market segmentation on Competitive Landscape Eli Lily and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Mylan N.V, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Fresenius Kabi AG and Ingenus Pharmaceuticals are some prominent gemcitabine HCl manufacturers profiled by Fact.MR’s report. Accord UK Ltd is a prominent gemcitabine producer, offering the gemcitabine 200 mg, gemcitabine 1000 mg and gemcitabine 2000 mg powders for solution infusion in vial forms. The powder is widely deployed to treat locally advanced bladder cancer in combination with cisplatin. Likewise, Pfizer Inc. also offers the GEMCITABINE 1 g/50 mL and 2g/50 mL lyophilized powders respectively. These powders are extensively deployed for intravenous use in ovarian cancer, breast cancer, non-small cell lung cancer and pancreatic cancer respectively. For in-depth Competitive Analysis, Check here More Insights on the Gemcitabine HCL Market Fact.MR, in its new offering, offers a comprehensive assessment of the global gemcitabine HCL market. The study provides readers with essential insights on the gemcitabine HCL market on the basis of type (branded and generic), application (Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-small-cell lung carcinoma (NSCLC), and Others), end users (Hospitals, Cancer Centers, and Others), and across key regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa). Explore Fact.MR’s Coverage on the Healthcare Domain eCOA, eSource and Clinical Trials Market: Fact.MR’s report on the eCOA, eSource and clinical trials market delves into an incisive analysis of the prominent expansion drivers likely to influence growth trajectory in the near future. Details about key segments, prominent geographical prominence and competitive landscape have been embedded within the scope of this report. Gonorrhea Therapeutics Market: Fact.MR’s report on the gonorrhea therapeutics market delves into an incisive analysis of the prominent expansion drivers likely to influence growth trajectory in the near future. Details about key segments, prominent geographical prominence and competitive landscape have been embedded within the scope of this report. Autologous Fat Grafting Market: Fact.MR’s report on the autologous fat grafting market delves into an incisive analysis of the prominent expansion drivers likely to influence growth trajectory in the near future. Details about key segments, prominent geographical prominence and competitive landscape have been embedded within the scope of this report. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583

机构